Repligen: New CFO 'suited to growth path,' hints at acquisitions
Protein A manufacturer Repligen has hired a CFO and says it is on the lookout for acquisition opportunities.
Archives for July 17, 2014
UK industry groups want Drs to use biosimilar names not INNs
UK industry groups have rejected the idea their call for doctors to use brand names rather than INNs in new biosimilars FAQ documents is about protecting member firms’ market share.
Cipla acquires mAb manufacturer Mabpharm
Indian biopharma Cipla is pushing further into the realm of monoclonal antibody manufacturing with its purchase of India-based Mabpharm.
Novartis sees biosimilars growth as a driving force in Q2 results
With almost three decades of recombinant protein production experience, Novartis is now seeing its work paying off as its biosimilars grew by 23% over the same quarter last year to $420m (€310.5m) in Q2.
Biosimilars will not erode sales like generics, says J&J
Biosimilars are not analogous to small molecule generics in terms of market share loss according to Johnson & Johnson, which is confident its biopharmaceutical portfolio can withstand competition.